Xabier G. de Albeniz (@xabieradrian) 's Twitter Profile
Xabier G. de Albeniz

@xabieradrian

ID: 302572489

calendar_today21-05-2011 12:13:07

83 Tweet

111 Followers

91 Following

Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

#Causalinference that talks the talk and walks the walk. Claim: "Continuing #breastcancer screening past age 75 doesn't reduce 8-year breast cancer mortality." Emulation of a #TargetTrial led by Xabier G. de Albeniz with Medicare data doi.org/10.7326/M18-11… Let the discussion start.

#Causalinference that talks the talk and walks the walk.

Claim: "Continuing #breastcancer screening past age 75 doesn't reduce 8-year breast cancer mortality."

Emulation of a #TargetTrial led by <a href="/xabieradrian/">Xabier G. de Albeniz</a> with Medicare data
doi.org/10.7326/M18-11…

Let the discussion start.
Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

BREAKING: Randomized trial EPICOS will study #tenofovir for the prevention of #COVID19 in 4000 health care workers in Spain. Participants will receive tenofovir (an HIV drug) or hydroxychloroquine (a malaria drug) or both or placebo. Led by Julia del Amo clinicaltrials.gov/ct2/show/NCT04…

Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

BREAKING: Risk of #COVID19 hospitalization in 77,590 persons with #HIV by antiretroviral type: TDF/FTC: 10.5 TAF/FTC: 20.3 ABC/3TC: 23.4 Other: 20.0 per 10,000 (Febr-April 2020) WANTED: Randomized trials of TDF/FTC (Tenofovir/Emtricitabine) doi.org/10.7326/M20-36…

BREAKING: Risk of #COVID19 hospitalization in 77,590 persons with #HIV by antiretroviral type:
   TDF/FTC: 10.5
   TAF/FTC: 20.3
   ABC/3TC: 23.4
   Other: 20.0
per 10,000 (Febr-April 2020) 

WANTED: Randomized trials of TDF/FTC (Tenofovir/Emtricitabine)

doi.org/10.7326/M20-36…
Betsy Ogburn (@betsyogburn) 's Twitter Profile Photo

My first ever podcast covered some of my current obsessions: the role of gatekeeping in causal inference; communicating the subtleties of causal inference in less siloed, more accessible ways & to a broader audience of quantitative methodologists; clinical research ethics

Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

No habrá vacuna en 2020, pero quizás sí fármacos baratos y seguros para prevenir #COVID19. Para averiguarlo, el ensayo clínico #EPICOS necesita voluntarios. Si eres personal sociosanitario, únete hoy a EPICOS. Escribe a Dra. Julia del Amo / Dra. Rosa Polo [email protected]

No habrá vacuna en 2020, pero quizás sí fármacos baratos y seguros para prevenir #COVID19.

Para averiguarlo, el ensayo clínico #EPICOS necesita voluntarios.

Si eres personal sociosanitario, únete hoy a EPICOS.

Escribe a Dra. Julia del Amo / Dra. Rosa Polo
epicos@sanidad.gob.es
Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

1/ Epidemiologists & other data scientists: Has anyone ever asked you whether you *adjusted* for competing events? If so, they didn't know what they were talking about. We don't *adjust* for competing events. We specify the causal estimand of interest and try to estimate it.

Barbra Dickerman (@barbradickerman) 's Twitter Profile Photo

Case-control studies are vulnerable to all the same biases that affect cohort studies, including time-varying confounding, selection bias, and immortal time bias. Here we extend the target trial approach to case-control designs to minimize these biases: bit.ly/36uXj3B

Case-control studies are vulnerable to all the same biases that affect cohort studies, including time-varying confounding, selection bias, and immortal time bias.

Here we extend the target trial approach to case-control designs to minimize these biases:

bit.ly/36uXj3B
Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

1/ We don't have a vaccine yet, but we have a treatment that may reduce the risk of #COVID19 by 20% without serious side effects. That treatment is #hydroxychloroquine. Risk ratio of COVID-19 in our meta-analysis of 3 prophylaxis randomized trials: 0.78 medrxiv.org/content/10.110…

1/ We don't have a vaccine yet, but we have a treatment that may reduce the risk of #COVID19 by 20% without serious side effects.

That treatment is #hydroxychloroquine.

Risk ratio of COVID-19 in our meta-analysis of 3 prophylaxis randomized trials: 0.78
medrxiv.org/content/10.110…
Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

@LSHTMstatmethod Harvard T.H. Chan School of Public Health Looking forward to tomorrow's discussion on how we learn what works for the treatment and prevention of #COVID19. Are observational studies reliable? Do we interpret randomized trials correctly? Any lessons for the next pandemic.. or this one?

CAUSALab (@causalab) 's Twitter Profile Photo

If you're interested in #causalinference from real world data, join hundreds of colleagues who have already registered for the CAUSALab Inaugural Event on November 5. In-person registration almost sold out. Online registration extended through November 2. causalab.sph.harvard.edu/symposia/

RTI Health Solutions (@rtihs) 's Twitter Profile Photo

Join Bradley Layton at the #FDASentinel Workshop in Session VI on Nov 9. The session will focus on pandemic response support, particularly #vaccinesafety protocols. Learn more ow.ly/Sljr50GEj6A #covid19

CAUSALab (@causalab) 's Twitter Profile Photo

Interested in #causalinference? Learn from top experts in the field. Summer courses offered at the Harvard T.H. Chan School of Public Health in June, 2022. 👉Key Topics in Causal Inference 👉Target Trial Emulation Stay tuned for more details. causalab.sph.harvard.edu/courses

Interested in #causalinference? 

Learn from top experts in the field.

Summer courses offered at the Harvard T.H. Chan School of Public Health in June, 2022.
👉Key Topics in Causal Inference 
👉Target Trial Emulation 

Stay tuned for more details.
causalab.sph.harvard.edu/courses
Barbra Dickerman (@barbradickerman) 's Twitter Profile Photo

Week 2 of the CAUSALab summer courses is all about how to emulate a #TargetTrial using healthcare databases. A combo of lectures + hands-on sessions in R/SAS. Come join us! Registration now open: ow.ly/H50b50I6hFU

Week 2 of the <a href="/CAUSALab/">CAUSALab</a> summer courses is all about how to emulate a #TargetTrial using healthcare databases.

A combo of lectures + hands-on sessions in R/SAS.

Come join us! 

Registration now open: ow.ly/H50b50I6hFU
Barbra Dickerman (@barbradickerman) 's Twitter Profile Photo

🚀New CAUSALab summer course!🚀 Advanced Confounding Adjustment Learn to implement g-methods (IP weighting, parametric g-formula) in the settings of time-fixed and time-varying treatment. 4 days of lectures + hands-on sessions in R/SAS. Register here! causalab.sph.harvard.edu/courses/

🚀New <a href="/CAUSALab/">CAUSALab</a> summer course!🚀
Advanced Confounding Adjustment

Learn to implement g-methods (IP weighting, parametric g-formula) in the settings of time-fixed and time-varying treatment.

4 days of lectures + hands-on sessions in R/SAS.

Register here! causalab.sph.harvard.edu/courses/
CAUSALab (@causalab) 's Twitter Profile Photo

Registration for the highly anticipated #2024CAUSALabcourses is now OPEN! Join us this summer Harvard T.H. Chan School of Public Health or #online. Secure your seat today! Visit our website for more information about enrollment and how to register causalab.sph.harvard.edu/courses/ #causalab #harvardchan

Registration for the highly anticipated #2024CAUSALabcourses is now OPEN!

Join us this summer <a href="/HarvardChanSPH/">Harvard T.H. Chan School of Public Health</a> or #online.

Secure your seat today! Visit our website for more information about enrollment and how to register causalab.sph.harvard.edu/courses/

#causalab #harvardchan
Miguel Hernán (@_miguelhernan) 's Twitter Profile Photo

Upgrade your #causalinference arsenal. A revision of our book "Causal Inference: What If" is available at miguelhernan.org/whatifbook Thanks to everyone who suggested improvements, reported typos, and proposed new citations and material. Enjoy the #WhatIfBook. Also, it's free.

Upgrade your #causalinference arsenal.

A revision of our book "Causal Inference: What If" is available at miguelhernan.org/whatifbook 

Thanks to everyone who suggested improvements, reported typos, and proposed new citations and material.

Enjoy the #WhatIfBook. Also, it's free.
Xabier G. de Albeniz (@xabieradrian) 's Twitter Profile Photo

The course will have protected time to address participants’ questions on their own observational studies. I look forward to engaging in these interesting discussions!!